Login to Your Account



Earnings Roundup

Amgen Previews 2011 Sales of Neulasta, Xgeva, Prolia

By Karen Pihl-Carey
BioWorld Today Contributing Writer

Tuesday, January 10, 2012

Providing an early sales glance, Amgen Inc. CEO-elect Bob Bradway reported Monday that the company's denosumab franchise, consisting of Xgeva and Prolia, generated more than $500 million in revenue in 2011, their first full year on the market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription